Acerus Pharmaceuticals Corp (ASP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
November 2018
58
About the Report
About the Report
Summary
Acerus Pharmaceuticals Corp (Acerus), formerly Trimel Pharmaceuticals Corporation develops, manufactures, markets and distributes novel innovative branded products. It focuses on providing men's and women's health. The company uses its proprietary drug delivery technology platforms, which include a bioadhesive nasal gel and the TriVair Deposition/Dispersion System, for the delivery of its products. Its product portfolio includes Estrace, which is approved in Canada for relief from menopausal symptoms; and Natesto, a testosterone nasal gel, which is approved by the US FDA for the treatment of male hypogonadism and filed for approval in Canada. Acerus is also developing Tefina (testosterone nasal gel) for women with female sexual dysfunction. Acerus is headquartered in Mississauga, Ontario, Canada.
Acerus Pharmaceuticals Corp (ASP)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Acerus Pharmaceuticals Corp, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Acerus Pharmaceuticals Corp, Medical Devices Deals, 2012 to YTD 2018 10
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Trimel Pharma Acquires Canadian Rights to Estrace from Shire for USD41.3 Million 13
Partnerships 15
Trimel Pharma Enters Into Co-Development Agreement With European Company 15
Licensing Agreements 16
Acerus Pharma Enters into Licensing Agreement with Pharmanest 16
Producto Cientificos Enters into Licensing Agreement with Acerus Pharma 17
Acerus Pharma Enters into Distributor and Licensing Agreement with Metuchen Pharma 18
Acerus Pharma Enters into Licensing Agreement with Viramal 19
Apsen Farmaceutica Enters into Licensing Agreement with Acerus Pharma 20
Eu Hwa Enters into Licensing Agreement with Acerus Pharma for NATESTO 21
medac Enters into Licensing Agreement with Acerus Pharma for NATESTO 22
Therios Healthcare Enters into Licensing Agreement with Acerus Pharma for NATESTO 23
Aytu BioScience Enters into Licensing Agreement with Acerus Pharma 24
Acerus Pharma Enters into Licensing Agreement with Medinova 25
Acerus Pharma Enters into Licensing and Distribution Agreement with Innovus Pharma 26
Equity Offering 27
Acerus Pharma Raises USD5.1 Million in Private Placement of Units 27
Acerus Pharma Raises USD2 Million in Private Placement of Shares 29
Trimel Pharma Raises USD16.6 Million in Private Placement of Shares 30
Acerus Pharma Raises USD2.1 Million in Private Placement of Shares 31
Trimel Pharma Announces Full Exercise Of Underwriter's Option For Public Offering Of Shares For USD 45 Million 32
Trimel Pharma Announces Rights Offering Of Shares 34
Trimel Pharma Completes Public Offering Of Units For USD 13 Million 35
Debt Offering 37
Trimel Pharma Raises USD25 Million in Private Placement of 9.5% Convetible Note Due 2015 37
Acerus Pharmaceuticals Corp-Key Competitors 38
Acerus Pharmaceuticals Corp-Key Employees 39
Acerus Pharmaceuticals Corp-Locations And Subsidiaries 40
Head Office 40
Other Locations & Subsidiaries 40
Recent Developments 41
Financial Announcements 41
Aug 13, 2018: Acerus Reports second quarter 2018 financial results 41
May 15, 2018: Acerus Reports First Quarter 2018 Financial Results 44
Nov 07, 2017: Acerus Reports Third Quarter 2017 Financial Results 46
Aug 11, 2017: Acerus Reports Second Quarter 2017 Financial Results 48
Mar 08, 2017: Acerus Reports Fourth Quarter and Full Year 2016 Financial Results 50
Corporate Communications 52
Jun 05, 2018: Acerus Announces Resignation Of Luc Mainville As Director 52
Mar 29, 2018: Acerus Announces Executive Leadership Change 53
Dec 07, 2017: Acerus Appoints Mr. Mark Lievonen to its Board of Directors 54
Oct 02, 2017: Acerus Announces Executive Leadership Change 55
May 05, 2017: Acerus Announces Appointment of Ken Yoon as Chief Financial Officer 56
Legal and Regulatory 57
Apr 10, 2018: Acerus Announces Settlement of Melnyk Litigation 57
Appendix 58
Methodology 58
About GlobalData 58
Contact Us 58
Disclaimer 58
List of Figure
List of Figures
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Acerus Pharmaceuticals Corp, Medical Devices Deals, 2012 to YTD 2018 10
List of Table
List of Tables
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Acerus Pharmaceuticals Corp, Deals By Therapy Area, 2012 to YTD 2018 9
Acerus Pharmaceuticals Corp, Medical Devices Deals, 2012 to YTD 2018 10
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Trimel Pharma Acquires Canadian Rights to Estrace from Shire for USD41.3 Million 13
Trimel Pharma Enters Into Co-Development Agreement With European Company 15
Acerus Pharma Enters into Licensing Agreement with Pharmanest 16
Producto Cientificos Enters into Licensing Agreement with Acerus Pharma 17
Acerus Pharma Enters into Distributor and Licensing Agreement with Metuchen Pharma 18
Acerus Pharma Enters into Licensing Agreement with Viramal 19
Apsen Farmaceutica Enters into Licensing Agreement with Acerus Pharma 20
Eu Hwa Enters into Licensing Agreement with Acerus Pharma for NATESTO 21
medac Enters into Licensing Agreement with Acerus Pharma for NATESTO 22
Therios Healthcare Enters into Licensing Agreement with Acerus Pharma for NATESTO 23
Aytu BioScience Enters into Licensing Agreement with Acerus Pharma 24
Acerus Pharma Enters into Licensing Agreement with Medinova 25
Acerus Pharma Enters into Licensing and Distribution Agreement with Innovus Pharma 26
Acerus Pharma Raises USD5.1 Million in Private Placement of Units 27
Acerus Pharma Raises USD2 Million in Private Placement of Shares 29
Trimel Pharma Raises USD16.6 Million in Private Placement of Shares 30
Acerus Pharma Raises USD2.1 Million in Private Placement of Shares 31
Trimel Pharma Announces Full Exercise Of Underwriter's Option For Public Offering Of Shares For USD 45 Million 32
Trimel Pharma Announces Rights Offering Of Shares 34
Trimel Pharma Completes Public Offering Of Units For USD 13 Million 35
Trimel Pharma Raises USD25 Million in Private Placement of 9.5% Convetible Note Due 2015 37
Acerus Pharmaceuticals Corp, Key Competitors 38
Acerus Pharmaceuticals Corp, Key Employees 39
Acerus Pharmaceuticals Corp, Subsidiaries 40
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.